Compare BUR & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BUR | DRTS |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | Guernsey | Israel |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2017 | 2021 |
| Metric | BUR | DRTS |
|---|---|---|
| Price | $4.40 | $14.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $13.58 | $8.67 |
| AVG Volume (30 Days) | ★ 1.6M | 492.6K |
| Earning Date | 05-06-2026 | 05-18-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $413,360,000.00 | N/A |
| Revenue This Year | $104.62 | N/A |
| Revenue Next Year | N/A | $699.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.59 | $3.18 |
| 52 Week High | $14.05 | $15.02 |
| Indicator | BUR | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 51.46 | 63.87 |
| Support Level | $4.15 | $6.47 |
| Resistance Level | $4.53 | $14.75 |
| Average True Range (ATR) | 0.18 | 0.61 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 65.55 | 87.42 |
Burford Capital Ltd provides capital against the underlying value of litigation and legal assets, known as legal finance, serving the legal industry with financial products and services. Its business is funding clients engaged in ongoing legal disputes to pay legal fees and monetize the expected future value of disputes, focusing on large, complex matters. The company has two reportable segments: Principal Finance, which earns maximum revenue and allocates capital to legal finance assets from its balance sheet and through interests in private funds managed by the company, and Asset Management and Other Services, which manages legal finance assets for third-party investors and provides other services to the legal industry.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.